Yes, trazodone is commonly prescribed off-label at low nighttime doses (often 25 mg) to improve sleep onset and maintenance. This use is not licensed in the UK, so it should be initiated only after a prescriber evaluates the risk-benefit balance for the individual.
In the UK, standard trazodone tablets are typically imprinted with the dosage strength (e.g., “25 mg”) and a letter code identifying the manufacturer. Exact markings can vary between generic suppliers.
Trazodone is not a controlled substance and is generally not screened for in routine workplace or athletic drug tests. However, specific testing panels may include it if requested.
Because trazodone can cause orthostatic hypotension, concurrent use with blood-pressure-lowering drugs may increase the risk of dizziness or fainting. Monitoring blood pressure after dose adjustments is advisable.
Patients often notice some improvement within 1-2 weeks, but full antidepressant effects may require 4-6 weeks of consistent therapy at an adequate dose.
Abrupt discontinuation after several weeks of therapy may lead to rebound insomnia or mood changes. It is recommended to discuss a tapering schedule with your prescriber before stopping.
There are no specific food bans, but large amounts of grapefruit juice should be avoided because it can increase trazodone blood levels via CYP3A4 inhibition.
Seek emergency medical care immediately. Priapism is a medical emergency that requires prompt treatment to prevent permanent damage.
St. John’s Wort, an herbal antidepressant, also affects serotonin pathways and can increase the risk of serotonin syndrome when combined with trazodone. Always inform your healthcare provider about any supplements you use.
Trazodone blocks certain serotonin receptors (5-HT₂A) while inhibiting reuptake, giving it a sedative profile not typical of selective serotonin reuptake inhibitors (SSRIs). This makes it useful when sleep disturbance is a prominent symptom.
Trazodone is an antidepressant medication that belongs to the class of serotonin antagonist and reuptake inhibitors (SARIs). It is available in oral tablet form in strengths of 25 mg, 50 mg, and 100 mg. In the United Kingdom, trazodone is a prescription-only medicine (POM) regulated by the Medicines and Healthcare products Regulatory Agency (MHRA).
This article covers trazodone, its pharmacology, approved and off-label uses, safety considerations, dosing guidance, and practical patient information.
Trazodone exerts its therapeutic effect primarily by influencing serotonin, a neurotransmitter involved in mood regulation.
The onset of antidepressant action typically appears after 1-2 weeks of consistent use, with full therapeutic benefit often reached after 4-6 weeks. The drug is well absorbed from the gastrointestinal tract, with peak plasma concentrations occurring about 1 hour after oral administration. It is extensively metabolised in the liver, primarily by CYP3A4, and its metabolites are eliminated via the kidneys.
Trazodone is frequently prescribed off-label to manage primary insomnia, especially when sleep onset or maintenance is disrupted. Although not licensed for this purpose in the UK, clinical practice guidelines acknowledge its utility at low nighttime doses (often 25 mg).
Disclaimer: Off-label use requires medical supervision and individualized risk assessment. The prescribing clinician must weigh potential benefits against risks such as daytime sedation or orthostatic hypotension.
Some clinicians use trazodone as an adjunct for chronic pain syndromes (e.g., fibromyalgia) because of its serotonergic modulation. Evidence is limited to small studies and case series; therefore, it remains an off-label indication.
If you are taking multiple medications, inform your pharmacist or prescriber before starting trazodone.
Dosing must be individualized by a qualified healthcare provider.
If you forget a dose, take it as soon as you remember provided it is at least 6 hours before the next scheduled dose. Do not double-dose.
Signs of overdose may include extreme drowsiness, hypotension, cardiac arrhythmias, or seizures. Seek emergency medical assistance immediately; treatment is supportive, with close cardiac monitoring. Activated charcoal may be considered if presentation is early.
Trazodone does not typically require a taper for short-term use, but abrupt cessation after prolonged therapy may provoke rebound insomnia or mood destabilisation. Discuss a gradual reduction plan with your prescriber if you have been on the medication for several months.
This article provides educational information about trazodone and is not a substitute for professional medical advice. Treatment decisions, including use for unapproved indications, must be made under the guidance of a qualified healthcare provider. The content is intended for informational purposes and does not constitute medical recommendations. Always consult a physician before starting, stopping, or changing any medication regimen.
